American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Evaluation of the PI3Kδ Inhibitor ME-401 in Patients with Relapsed/Refractory Follicular Lymphoma

ASCO 2019 – CLL

In a phase 1b study, the novel PI3kδ inhibitor ME-401 showed promising response rates with acceptable tolerability when evaluated in a flexible dosing schedule in follicular lymphoma. Additional studies are enrolling patients to further evaluate the clinical potential for this investigative therapy. Read More ›

Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL

ASCO 2019 – CLL

A novel combination of venetoclax, atezolizumab, and obinutuzumab is being studied in patients with Richter transformation of CLL into diffuse large B-cell lymphoma. Read More ›

Smart Start: Final Results of Rituximab, Lenalidomide, and Ibrutinib Lead-In Therapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

ASCO 2019 – CLL

The combination of rituximab, lenalidomide, and ibrutinib as lead-in therapy prior to chemotherapy is effective in patients with newly diagnosed diffuse large B-cell lymphoma. Read More ›

Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL

ASCO 2019 – CLL

In an ongoing phase 1/2 trial, the investigational CAR T therapy lisocabtagene maraleucel induced deep and durable responses, with many patients achieving minimal residual disease (MRD) status to date. Read More ›

Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE

ASCO 2019 – CLL

Newly reported findings from the iNNOVATE study corroborate earlier reports that ibrutinib has a positive impact on patient-reported outcomes in Waldenström’s macroglobulinemia (WM). Read More ›

Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM

ASCO 2019 – CLL

In a retrospective analysis, the doublet combination of rituximab plus bendamustine showed better response rates and event-free survival rates than 2 different triplet regimens when given as frontline treatment of Waldenström’s macroglobulinemia (WM). Read More ›

Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL

ASCO 2019 – CLL

Newly reported findings from the iNNOVATE study corroborate earlier reports that ibrutinib has a positive impact on patient-reported outcomes in Waldenström’s macroglobulinemia. Read More ›

Impact of t(11;14) on Outcomes in African American and Non–African American Patients with NDMM: Connect MM Registry

ASCO 2017 – Multiple Myeloma

Data from the Connect MM Registry show poor survival outcomes in African American patients with newly diagnosed multiple myeloma (NDMM) and t(11;14) mutation. Read More ›

Immunophenotypic and Quantitative Impacts of Ibrutinib and Chlorambucil on Circulating Immune Cells in CLL

ASCO 2017 – CLL

A quantitative analysis revealed substantially different activity profiles for ibrutinib and chlorambucil in the circulating cells during the first year of treatment in patients with chronic lymphocytic leukemia (CLL). Read More ›

COSMOS: A 2-Cohort, Phase 2 Study of MOR208 plus Idelalisib or Venetoclax in Patients with R/R CLL/SLL Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor

ASCO 2017 – CLL

This 2-cohort, phase 2 study will investigate a CD19 antibody, MOR208, combined with idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a Bruton’s tyrosine kinase inhibitor. Read More ›

American Society of Clinical Oncology (ASCO)

Page 14 of 31